β3-Adrenoceptors in the cardiovascular system: Putative roles in human pathologies

Pharmacology and Therapeutics

Volumn 111, Issue 3, 2006, Pages 652-673

  Rozec, Bertrand ^a,b   Gauthier, Chantal ^a,c  

^a L INSTITUT DU THORAX   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE NANTES   (France)

Author keywords

adrenergic receptors; Contractility; Heart; Heart failure; Hypertension; Vessels

Indexed keywords

1 (2 ETHYLPHENOXY) 3 (1,2,3,4 TETRAHYDRO 1 NAPHTHYLAMINO) 2 PROPANOL OXALATE; 4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; 4 [2 [(2 HYDROXY 2 PHENYLETHYL)AMINO]ETHOXY]PHENYLACETIC ACID; 4 [2 [(2 HYDROXY 2 PHENYLETHYL)AMINO]PROPYL]BENZOIC ACID METHYL ESTER HYDROGEN MALEATE; 4 [2 [(2 HYDROXY 3 PHENOXYPROPYL)AMINO]ETHOXY]PHENOXYACETIC ACID; 4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; 5 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,3 BENZODIOXOLE 2,2 DICARBOXYLIC ACID; [[7 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO] 5,6,7,8 TETRAHYDRO 2 NAPHTHYL]OXY]ACETIC ACID ETHYL ESTER; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 1 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 3 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; BUPRANOLOL; ISOPRENALINE; L 748328; L 748337; L 755507; L 796568; L 796598; METOPROLOL; N [4 [2 [[3 [3 (ACETAMIDOMETHYL)PHENOXY] 2 HYDROXYPROPYL]AMINO]ETHYL] PHENYL]BENZENESULFONAMIDE; N [4 [2 [[3 [3 (AMINOSULFONYL)PHENOXY] 2 HYDROXYPROPYL]AMINO]ETHYL]PHENYL] BENZENESULFONAMIDE; NADOLOL; NEBIVOLOL; NORADRENALIN; PINDOLOL; PRAZOSIN; SR 59104A; SR 59119A; TERTATOLOL; U 44619; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADRENERGIC SYSTEM; ARTERY RESISTANCE; BINDING AFFINITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CAROTID ARTERY; CELL PROLIFERATION; CHRONOTROPISM; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DNA POLYMORPHISM; DRUG EFFECT; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; EXON; GENE LOCATION; GENE MUTATION; GENETIC VARIABILITY; HEART FAILURE; HEART FUNCTION; HEART MUSCLE; HEART MUSCLE CELL; HEART PROTECTION; HEART RATE; HEART REPOLARIZATION; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO CULTURE; IN VIVO STUDY; INOTROPISM; INTRON; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; VASODILATATION; WESTERN BLOTTING; WHOLE CELL; AMINO ACID SEQUENCE; ANIMAL; BLOOD VESSEL; CHEMISTRY; CONGESTIVE HEART FAILURE; GENETICS; HEART CONTRACTION; LUNG CIRCULATION; MOLECULAR GENETICS; PHYSIOLOGY; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANIMALS; BLOOD VESSELS; CORONARY DISEASE; DIABETES MELLITUS; HEART FAILURE, CONGESTIVE; HEART RATE; HUMANS; HYPERTENSION; MOLECULAR SEQUENCE DATA; MYOCARDIAL CONTRACTION; OBESITY; PULMONARY CIRCULATION; RECEPTORS, ADRENERGIC, BETA-3; SIGNAL TRANSDUCTION;

EID: 33746490589     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2005.12.002     Document Type: Review

References (218)

1. Agarwal A., Williams G.H., and Fisher N.D. Genetics of human hypertension. Trends Endocrinol Metab 16 3 (2005) 127-133
2. Arch J.R. Beta(3)-adrenoceptor agonists: potential, pitfalls and progress. Eur J Pharmacol 440 2-3 (2002) 99-107
3. Arch J.R., Ainsworth A.T., Cawthorne M.A., Piercy V., Sennitt M.V., Thody V.E., et al. Atypical beta-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature 309 5964 (1984) 163-165
4. Arch J.R., and Kaumann A.J. Beta 3 and atypical beta-adrenoceptors. Med Res Rev 13 6 (1993) 663-729
5. Arch J.R., and Wilson S. Beta 3-adrenoceptors and the regulation of metabolism in adipose tissues. Biochem Soc Trans 24 2 (1996) 412-418
6. Atef N., Lafontan M., Double A., Helary C., Ktorza A., and Penicaud L. A specific beta 3-adrenoceptor agonist induces increased pancreatic islet blood flow and insulin secretion in rats. Eur J Pharmacol 298 3 (1996) 287-292
7. Baba T., Nakajima S., and Yajima Y. Beta3-adrenergic receptor gene polymorphism is not associated with hypertension in NIDDM patients without nephropathy. Horm Metab Res 30 10 (1998) 629-632
8. Barbe P., Millet L., Galitzky J., Lafontan M., and Berlan M. In situ assessment of the role of the beta 1-, beta 2- and beta 3-adrenoceptors in the control of lipolysis and nutritive blood flow in human subcutaneous adipose tissue. Br J Pharmacol 117 5 (1996) 907-913
9. Beavo J.A. cGMP inhibition of heart phosphodiesterase: is it clinically relevant?. J Clin Invest 95 2 (1995) 445
10. Begin-Heick N. Beta 3-adrenergic activation of adenylyl cyclase in mouse white adipocytes: modulation by GTP and effect of obesity. J Cell Biochem 58 4 (1995) 464-473
11. Berlan M., Galitzky J., Bousquet-Melou A., Lafontan M., and Montastruc J.L. Beta-3 adrenoceptor-mediated increase in cutaneous blood flow in the dog. J Pharmacol Exp Ther 268 3 (1994) 1444-1451
12. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 344 22 (2001) 1659-1667
13. Bianchetti A., and Manara L. In vitro inhibition of intestinal motility by phenylethanolaminotetralines: evidence of atypical beta-adrenoceptors in rat colon. Br J Pharmacol 100 4 (1990) 831-839
14. Blin N., Camoin L., Maigret B., and Strosberg A.D. Structural and conformational features determining selective signal transduction in the beta 3-adrenergic receptor. Mol Pharmacol 44 6 (1993) 1094-1104
15. Bloch W., Fleischmann B.K., Lorke D.E., Andressen C., Hops B., Hescheler J., et al. Nitric oxide synthase expression and role during cardiomyogenesis. Cardiovasc Res 43 3 (1999) 675-684
16. Boonen H.C., Daemen M.J., Eerdmans P.H., Fazzi G.E., van Kleef E.M., Schiffers P.M., et al. Mesenteric small artery changes after vasoconstrictor infusion in young rats. J Cardiovasc Pharmacol 22 3 (1993) 388-395
17. Booth J.V., Landolfo K.P., Chesnut L.C., Bennett-Guerrero E., Gerhardt M.A., and Atwell D.M. Acute depression of myocardial beta-adrenergic receptor signaling during cardiopulmonary bypass: impairment of the adenylyl cyclase moiety. Duke Heart Center Perioperative Desensitization Group. Anesthesiology 89 3 (1998) 602-611
18. Borkowski K.R., Gros R., and Schneider H. Vascular beta-adrenoceptor-mediated responses in hypertension and ageing in rats. J Auton Pharmacol 12 6 (1992) 389-401
19. Bosch R.F., Schneck A.C., Kiehn J., Zhang W., Hambrock A., Eigenberger B.W., et al. Beta3-adrenergic regulation of an ion channel in the heart-inhibition of the slow delayed rectifier potassium current I(Ks) in guinea pig ventricular myocytes. Cardiovasc Res 56 3 (2002) 393-403
20. Brahmadevara N., Shaw A.M., and MacDonald A. Evidence against beta 3-adrenoceptors or low affinity state of beta 1-adrenoceptors mediating relaxation in rat isolated aorta. Br J Pharmacol 138 1 (2003) 99-106
21. Brawley L., Shaw A.M., and MacDonald A. Role of endothelium/nitric oxide in atypical beta-adrenoceptor-mediated relaxation in rat isolated aorta. Eur J Pharmacol 398 2 (2000) 285-296
22. Briones A.M., Daly C.J., Jimenez-Altayo F., Martinez-Revelles S., Gonzalez J.M., McGrath J.C., et al. Direct demonstration of beta(1)- and evidence against beta(2)- and beta(3)-adrenoceptors, in smooth muscle cells of rat small mesenteric arteries. Br J Pharmacol (2005)
23. Bristow M.R., Ginsburg R., Umans V., Fowler M., Minobe W., Rasmussen R., et al. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 59 3 (1986) 297-309
24. Campbell D.L., Stamler J.S., and Strauss H.C. Redox modulation of L-type calcium channels in ferret ventricular myocytes. Dual mechanism regulation by nitric oxide and S-nitrosothiols. J Gen Physiol 108 4 (1996) 277-293
25. Candelore M.R., Deng L., Tota L., Guan X.M., Amend A., Liu Y., et al. Potent and selective human beta(3)-adrenergic receptor antagonists. J Pharmacol Exp Ther 290 2 (1999) 649-655
26. Carrel T., Kujawski T., Zund G., Schwitter J., Amann F.W., Gallino A., et al. The internal mammary artery malperfusion syndrome: incidence, treatment and angiographic verification. Eur J Cardiothorac Surg 9 4 (1995) 190-195
27. Carvalho M.H., Scivoletto R., Fortes Z.B., Nigro D., and Cordellini S. Reactivity of aorta and mesenteric microvessels to drugs in spontaneously hypertensive rats: role of the endothelium. J Hypertens 5 3 (1987) 377-382
28. Chamberlain P.D., Jennings K.H., Paul F., Cordell J., Berry A., Holmes S.D., et al. The tissue distribution of the human beta3-adrenoceptor studied using a monoclonal antibody: direct evidence of the beta3-adrenoceptor in human adipose tissue, atrium and skeletal muscle. Int J Obes Relat Metab Disord 23 10 (1999) 1057-1065
29. Chaudhry A., MacKenzie R.G., Georgic L.M., and Granneman J.G. Differential interaction of beta 1- and beta 3-adrenergic receptors with Gi in rat adipocytes. Cell Signal 6 4 (1994) 457-465
30. Chen J., Radford M.J., Wang Y., Marciniak T.A., and Krumholz H.M. Are beta-blockers effective in elderly patients who undergo coronary revascularization after acute myocardial infarction?. Arch Intern Med 160 7 (2000) 947-952
31. Cheng H.J., Zhang Z.S., Onishi K., Ukai T., Sane D.C., and Cheng C.P. Upregulation of functional beta(3)-adrenergic receptor in the failing canine myocardium. Circ Res 89 7 (2001) 599-606
32. Chruscinski A., Brede M.E., Meinel L., Lohse M.J., Kobilka B.K., and Hein L. Differential distribution of beta-adrenergic receptor subtypes in blood vessels of knockout mice lacking beta(1)- or beta(2)-adrenergic receptors. Mol Pharmacol 60 5 (2001) 955-962
33. Cirino G., Sorrentino R., di Villa B.R., Popolo A., Palmieri A., Imbimbo C., et al. Involvement of beta 3-adrenergic receptor activation via cyclic GMP-but not NO-dependent mechanisms in human corpus cavernosum function. Proc Natl Acad Sci USA 100 9 (2003) 5531-5536
34. Clark B.J., and Bertholet A. Effects of pindolol on vascular smooth muscle. Gen Pharmacol 14 1 (1983) 117-119
35. Clement K., Vaisse C., Manning B.S., Basdevant A., Guy-Grand B., Ruiz J., et al. Genetic variation in the beta 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. N Engl J Med 333 6 (1995) 352-354
36. Cohen M.L., Bloomquist W., Kriauciunas A., Shuker A., and Calligaro D. Aryl propanolamines: comparison of activity at human beta3 receptors, rat beta3 receptors and rat atrial receptors mediating tachycardia. Br J Pharmacol 126 4 (1999) 1018-1024
37. Corella D., Guillen M., Portoles O., Sorli J.V., Alonso V., Folch J., et al. Gender specific associations of the Trp64Arg mutation in the beta3-adrenergic receptor gene with obesity-related phenotypes in a Mediterranean population: interaction with a common lipoprotein lipase gene variation. J Intern Med 250 4 (2001) 348-360
38. Czuriga I., Riecansky I., Bodnar J., Fulop T., Kruzsicz V., and Kristof E. Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). Cardiovasc Drugs Ther 17 3 (2003) 257-263
39. de Champlain J. Do most antihypertensive agents have a sympatholytic action?. Curr Hypertens Rep 3 4 (2001) 305-313
40. de Groot A.A., Mathy M.J., van Zwieten A., and Peters S.L. Involvement of the beta3 adrenoceptor in nebivolol-induced vasorelaxation in the rat aorta. J Cardiovasc Pharmacol 42 2 (2003) 232-236
41. De Mey J.G., and Vanhoutte P.M. Heterogeneous behavior of the canine arterial and venous wall. Importance of the endothelium. Circ Res 51 4 (1982) 439-447
42. De Ponti F., Gibelli G., Croci T., Arcidiaco M., Crema F., and Manara L. Functional evidence of atypical beta 3-adrenoceptors in the human colon using the beta 3-selective adrenoceptor antagonist, SR 59230A. Br J Pharmacol 117 7 (1996) 1374-1376
43. Dennedy M.C., Houlihan D.D., McMillan H., and Morrison J.J. Beta2- and beta3-adrenoreceptor agonists: human myometrial selectivity and effects on umbilical artery tone. Am J Obstet Gynecol 187 3 (2002) 641-647
44. Dessy C., Moniotte S., Ghisdal P., Havaux X., and Balligand J.L. Endothelial beta3-adrenoceptors mediate vasorelaxation of human coronary microarteries through nitric oxide and endothelium-dependent hyperpolarization. Circulation 110 8 (2004) 948-954
45. Dessy C., Saliez J., Ghisdal P., Daneau G., Lobysheva I.I., Frerart F., et al. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation 112 8 (2005) 1198-1205
46. Dincer U.D., Bidasee K.R., Guner S., Tay A., Ozcelikay A.T., and Altan V.M. The effect of diabetes on expression of beta1-, beta2-, and beta3-adrenoreceptors in rat hearts. Diabetes 50 2 (2001) 455-461
47. Doggrell S.A., and Surman A.J. Loss of maximum attenuation and receptor reserve for isoprenaline at the beta 2-adrenoceptors of the portal veins of hypertensive rats. J Hypertens 13 9 (1995) 1023-1029
48. Dolan J.A., Muenkel H.A., Burns M.G., Pellegrino S.M., Fraser C.M., Pietri F., et al. Beta-3 adrenoceptor selectivity of the dioxolane dicarboxylate phenethanolamines. J Pharmacol Exp Ther 269 3 (1994) 1000-1006
49. Donckier J.E., Massart P.E., Van Mechelen H., Heyndrickx G.R., Gauthier C., and Balligand J.L. Cardiovascular effects of beta 3-adrenoceptor stimulation in perinephritic hypertension. Eur J Clin Invest 31 8 (2001) 681-689
50. Dumas M., Dumas J.P., Bardou M., Rochette L., Advenier C., and Giudicelli J.F. Influence of beta-adrenoceptor agonists on the pulmonary circulation. Effects of a beta3-adrenoceptor antagonist, SR 59230A. Eur J Pharmacol 348 2-3 (1998) 223-228
51. Dumas J.P., Goirand F., Bardou M., Dumas M., Rochette L., Advenier C., et al. Role of potassium channels and nitric oxide in the relaxant effects elicited by beta-adrenoceptor agonists on hypoxic vasoconstriction in the isolated perfused lung of the rat. Br J Pharmacol 127 2 (1999) 421-428
52. Edvinsson L., and Owman C. Pharmacological characterization of adrenergic alpha and beta receptors mediating the vasomotor responses of cerebral arteries in vitro. Circ Res 35 6 (1974) 835-849
53. El-Armouche A., Zolk O., Rau T., and Eschenhagen T. Inhibitory G-proteins and their role in desensitization of the adenylyl cyclase pathway in heart failure. Cardiovasc Res 60 3 (2003) 478-487
54. Emorine L., Blin N., and Strosberg A.D. The human beta 3-adrenoceptor: the search for a physiological function. Trends Pharmacol Sci 15 1 (1994) 3-7
55. Emorine L.J., Marullo S., Briend-Sutren M.M., Patey G., Tate K., Delavier-Klutchko C., et al. Molecular characterization of the human beta 3-adrenergic receptor. Science 245 4922 (1989) 1118-1121
56. Endo K., Yanagi H., Hirano C., Hamaguchi H., Tsuchiya S., and Tomura S. Association of Trp64Arg polymorphism of the beta3-adrenergic receptor gene and no association of Gln223Arg polymorphism of the leptin receptor gene in Japanese schoolchildren with obesity. Int J Obes Relat Metab Disord 24 4 (2000) 443-449
57. Engelhardt S., Hein L., Keller U., Klambt K., and Lohse M.J. Inhibition of Na(+)-H(+) exchange prevents hypertrophy, fibrosis, and heart failure in beta(1)-adrenergic receptor transgenic mice. Circ Res 90 7 (2002) 814-819
58. Erhardt E., Czako M., Csernus K., Molnar D., and Kosztolanyi G. The frequency of Trp64Arg polymorphism of the beta3-adrenergic receptor gene in healthy and obese Hungarian children and its association with cardiovascular risk factors. Eur J Clin Nutr 59 8 (2005) 955-959
59. Evans B.A., Papaioannou M., Hamilton S., and Summers R.J. Alternative splicing generates two isoforms of the beta3-adrenoceptor which are differentially expressed in mouse tissues. Br J Pharmacol 127 6 (1999) 1525-1531
60. Feldman R.D. Beta-adrenergic receptor alterations in hypertension-physiological and molecular correlates. Can J Physiol Pharmacol 65 8 (1987) 1666-1672
61. Flather M.D., Shibata M.C., Coats A.J., Van Veldhuisen D.J., Parkhomenko A., Borbola J., et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26 3 (2005) 215-225
62. Forrest R.H., and Hickford J.G. Rapid communication: nucleotide sequences of the bovine, caprine, and ovine beta3-adrenergic receptor genes. J Anim Sci 78 5 (2000) 1397-1398
63. Friedman M., Wang S.Y., Stahl G.L., Johnson R.G., and Sellke F.W. Altered beta-adrenergic and cholinergic pulmonary vascular responses after total cardiopulmonary bypass. J Appl Physiol 79 6 (1995) 1998-2006
64. Furchgott R.F., and Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288 5789 (1980) 373-376
65. Galitzky J., Reverte M., Portillo M., Carpene C., Lafontan M., and Berlan M. Coexistence of beta 1-, beta 2-, and beta 3-adrenoceptors in dog fat cells and their differential activation by catecholamines. Am J Physiol 264 3 Pt 1 (1993) E403-E412
66. Gallego M., Espina L., and Casis O. Blood pressure responsiveness to sympathetic agonists in anaesthetised diabetic rats. J Physiol Biochem 58 2 (2002) 87-93
67. Gaudino M., Trani C., Luciani N., Alessandrini F., and Possati G. The internal mammary artery malperfusion syndrome: late angiographic verification. Ann Thorac Surg 63 5 (1997) 1257-1261
68. Gauthier C., Tavernier G., Charpentier F., Langin D., and Le Marec H. Functional beta3-adrenoceptor in the human heart. J Clin Invest 98 2 (1996) 556-562
69. Gauthier C., Leblais V., Kobzik L., Trochu J.N., Khandoudi N., Bril A., et al. The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. J Clin Invest 102 7 (1998) 1377-1384
70. Gauthier C., Tavernier G., Trochu J.N., Leblais V., Laurent K., Langin D., et al. Interspecies differences in the cardiac negative inotropic effects of beta(3)-adrenoceptor agonists. J Pharmacol Exp Ther 290 2 (1999) 687-693
71. Gauthier C., Langin D., and Balligand J.L. Beta3-adrenoceptors in the cardiovascular system. Trends Pharmacol Sci 21 11 (2000) 426-431
72. Germack R., and Dickenson J.M. Induction of {beta}3-adrenergic receptor functional expression following chronic stimulation with noradrenaline in neonatal rat cardiomyocytes. J Pharmacol Exp Ther 316 1 (2006) 392-402
73. i and contractility in isolated adult rabbit ventricular myocytes. Am J Physiol 271 4 Pt 2 (1996) H1449-H1455
74. Gosgnach W., Boixel C., Nevo N., Poiraud T., and Michel J.B. Nebivolol induces calcium-independent signaling in endothelial cells by a possible beta-adrenergic pathway. J Cardiovasc Pharmacol 38 2 (2001) 191-199
75. Granneman J.G. The putative beta4-adrenergic receptor is a novel state of the beta1-adrenergic receptor. Am J Physiol Endocrinol Metab 280 2 (2001) E199-E202
76. Granneman J.G., Lahners K.N., and Chaudhry A. Characterization of the human beta 3-adrenergic receptor gene. Mol Pharmacol 44 2 (1993) 264-270
77. Granneman J.G., Lahners K.N., and Rao D.D. Rodent and human beta 3-adrenergic receptor genes contain an intron within the protein-coding block. Mol Pharmacol 42 6 (1992) 964-970
78. Gross W.L., Bak M.I., Ingwall J.S., Arstall M.A., Smith T.W., Balligand J.L., et al. Nitric oxide inhibits creatine kinase and regulates rat heart contractile reserve. Proc Natl Acad Sci USA 93 11 (1996) 5604-5609
79. Guimaraes S., and Moura D. Vascular adrenoceptors: an update. Pharmacol Rev 53 2 (2001) 319-356
80. Hall R.A., Ostedgaard L.S., Premont R.T., Blitzer J.T., Rahman N., Welsh M.J., et al. A C-terminal motif found in the beta2-adrenergic receptor, P2Y1 receptor and cystic fibrosis transmembrane conductance regulator determines binding to the Na+/H+ exchanger regulatory factor family of PDZ proteins. Proc Natl Acad Sci USA 95 15 (1998) 8496-8501
81. Hao K., Peng S., Xing H., Yu Y., Huang A., Hong X., et al. Beta(3) adrenergic receptor polymorphism and obesity-related phenotypes in hypertensive patients. Obes Res 12 1 (2004) 125-130
82. Harris A., Chung H.S., Ciulla T.A., and Kagemann L. Progress in measurement of ocular blood flow and relevance to our understanding of glaucoma and age-related macular degeneration. Prog Retin Eye Res 18 5 (1999) 669-687
83. He G.W., Acuff T.E., Yang C.Q., Ryan W.H., and Mack M.J. Middle and proximal sections of the human internal mammary artery are not "passive conduits". J Thorac Cardiovasc Surg 108 4 (1994) 741-746
84. Hutchinson D.S., Bengtsson T., Evans B.A., and Summers R.J. Mouse beta 3a- and beta 3b-adrenoceptors expressed in Chinese hamster ovary cells display identical pharmacology but utilize distinct signalling pathways. Br J Pharmacol 135 8 (2002) 1903-1914
85. Iwase M., Ichikawa K., Tashiro K., Iino K., Shinohara N., Ibayashi S., et al. Effects of monosodium glutamate-induced obesity in spontaneously hypertensive rats vs. Wistar Kyoto rats: serum leptin and blood flow to brown adipose tissue. Hypertens Res 23 5 (2000) 503-510
86. Jockers R., Da Silva A., Strosberg A.D., Bouvier M., and Marullo S. New molecular and structural determinants involved in beta 2-adrenergic receptor desensitization and sequestration. Delineation using chimeric beta 3/beta 2-adrenergic receptors. J Biol Chem 271 16 (1996) 9355-9362
87. Johnstone M.T., Creager S.J., Scales K.M., Cusco J.A., Lee B.K., and Creager M.A. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 88 6 (1993) 2510-2516
88. Joseph S.S., Lynham J.A., Molenaar P., Grace A.A., Colledge W.H., and Kaumann A.J. Intrinsic sympathomimetic activity of (-)-pindolol mediated through a (-)-propranolol-resistant site of the beta1-adrenoceptor in human atrium and recombinant receptors. Naunyn Schmiedeberg's Arch Pharmacol 368 6 (2003) 496-503
89. Kathofer S., Zhang W., Karle C., Thomas D., Schoels W., and Kiehn J. Functional coupling of human beta 3-adrenoreceptors to the KvLQT1/MinK potassium channel. J Biol Chem 275 35 (2000) 26743-26747
90. Kaumann A.J., and Molenaar P. Differences between the third cardiac beta-adrenoceptor and the colonic beta 3-adrenoceptor in the rat. Br J Pharmacol 118 8 (1996) 2085-2098
91. Kaumann A.J., and Molenaar P. Modulation of human cardiac function through 4 beta-adrenoceptor populations. Naunyn Schmiedeberg's Arch Pharmacol 355 6 (1997) 667-681
92. Kaumann A., Bartel S., Molenaar P., Sanders L., Burrell K., Vetter D., et al. Activation of beta2-adrenergic receptors hastens relaxation and mediates phosphorylation of phospholamban, troponin I, and C-protein in ventricular myocardium from patients with terminal heart failure. Circulation 99 1 (1999) 65-72
93. Kawasuji M., Tedoriya T., Takemura H., Sakakibara N., Taki J., and Watanabe Y. Flow capacities of arterial grafts for coronary artery bypass grafting. Ann Thorac Surg 56 4 (1993) 957-962
94. Kitamura T., Onishi K., Dohi K., Okinaka T., Isaka N., and Nakano T. The negative inotropic effect of beta3-adrenoceptor stimulation in the beating guinea pig heart. J Cardiovasc Pharmacol 35 5 (2000) 786-790
95. Klaus S., Muzzin P., Revelli J.P., Cawthorne M.A., Giacobino J.P., and Ricquier D. Control of beta 3-adrenergic receptor gene expression in brown adipocytes in culture. Mol Cell Endocrinol 109 2 (1995) 189-195
96. Klein R. Diabetic retinopathy. Annu Rev Public Health 17 (1996) 137-158
97. Kohout T.A., Takaoka H., McDonald P.H., Perry S.J., Mao L., Lefkowitz R.J., et al. Augmentation of cardiac contractility mediated by the human beta(3)-adrenergic receptor overexpressed in the hearts of transgenic mice. Circulation 104 20 (2001) 2485-2491
98. Kong Y.H., Li W.M., and Tian Y. Effect of beta3-adrenoreceptors agonist on beta3-adrenoreceptors expression and myocyte apoptosis in a rat model of heart failure. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 16 3 (2004) 142-147
99. Konishi M., and Su C. Role of endothelium in dilator responses of spontaneously hypertensive rat arteries. Hypertension 5 6 (1983) 881-886
100. Kozlowska H., Szymska U., Schlicker E., and Malinowska B. Atypical beta-adrenoceptors, different from beta 3-adrenoceptors and probably from the low-affinity state of beta 1-adrenoceptors, relax the rat isolated mesenteric artery. Br J Pharmacol 140 1 (2003) 3-12
101. Kozlowska H., Schlicker E., Kozlowski M., Siedlecka U., Laudanski J., and Malinowska B. Ligands at beta2-, beta3-, and the low-affinity state of beta1-adrenoceptors block the alpha1-adrenoceptor-mediated constriction in human pulmonary and rat mesenteric arteries. J Cardiovasc Pharmacol 46 1 (2005) 76-82
102. Krauss S.L., Dodge J.T., and Bevan J.A. Magnitude of beta-adrenoceptor-mediated responses of dog epicardial coronary arteries: inverse relation to diameter. Am J Physiol 263 5 Pt 2 (1992) H1422-H1429
103. Kubo S., Matsuda A., Ohnuki T., Hattori K., Suzuki J., and Nagatomo T. Assessment of beta 2- and beta 3-adrenoceptors in rat white adipose tissues by radioligand binding assay. Biol Pharm Bull 20 2 (1997) 142-148
104. Kupershmidt S., Yang T., Anderson M.E., Wessels A., Niswender K.D., Magnuson M.A., et al. Replacement by homologous recombination of the minK gene with lacZ reveals restriction of minK expression to the mouse cardiac conduction system. Circ Res 84 2 (1999) 146-152
105. Kurabayashi T., Carey D.G., and Morrison N.A. The beta 3-adrenergic receptor gene Trp64Arg mutation is overrepresented in obese women. Effects on weight, BMI, abdominal fat, blood pressure, and reproductive history in an elderly Australian population. Diabetes 45 10 (1996) 1358-1363
106. Kuratani K., Kodama H., and Yamaguchi I. Enhancement of gastric mucosal blood flow by beta-3 adrenergic agonists prevents indomethacin-induced antral ulcer in the rat. J Pharmacol Exp Ther 270 2 (1994) 559-565
107. Lacroix J.S., Kurt A.M., Auberson S., and Bretton C. Beta-adrenergic mechanisms in the nasal mucosa vascular bed. Eur Arch Otorhinolaryngol 252 5 (1995) 298-303
108. Lands A.M., Arnold A., McAuliff J.P., Luduena F.P., Brown T.G., et al. Differentiation of receptor systems activated by sympathomimetic amines. Nature 214 88 (1967) 597-598
109. Langin D., Portillo M.P., Saulnier-Blache J.S., and Lafontan M. Coexistence of three beta-adrenoceptor subtypes in white fat cells of various mammalian species. Eur J Pharmacol 199 3 (1991) 291-301
110. Larsen T.M., Toubro S., van Baak M.A., Gottesdiener K.M., Larson P., Saris W.H., et al. Effect of a 28-d treatment with L-796568, a novel beta(3)-adrenergic receptor agonist, on energy expenditure and body composition in obese men. Am J Clin Nutr 76 4 (2002) 780-788
111. Leblais V., Demolombe S., Vallette G., Langin D., Baro I., Escande D., et al. Beta3-adrenoceptor control the cystic fibrosis transmembrane conductance regulator through a cAMP/protein kinase A-independent pathway. J Biol Chem 274 10 (1999) 6107-6113
112. Lenzen G., Pietri-Rouxel F., Drumare M.F., Amiard A., Guillot S., Archimbault P., et al. Genomic cloning and species-specific properties of the recombinant canine beta3-adrenoceptor. Eur J Pharmacol 363 2-3 (1998) 217-227
113. Levasseur S., Pigeon C., Reyl-Desmars F., Caput D., and Lewin M.J. Stimulation of adenylate cyclase by the isoforms of human and rat beta-3 adrenergic receptor expressed in the CHO cells. Gastroenterol Clin Biol 19 8-9 (1995) 668-672
114. - channels in heart. Circ Res 71 4 (1992) 1002-1007
115. Liggett S.B. Functional properties of the rat and human beta 3-adrenergic receptors: differential agonist activation of recombinant receptors in Chinese hamster ovary cells. Mol Pharmacol 42 4 (1992) 634-637
116. Liggett S.B., Freedman N.J., Schwinn D.A., and Lefkowitz R.J. Structural basis for receptor subtype-specific regulation revealed by a chimeric beta 3/beta 2-adrenergic receptor. Proc Natl Acad Sci USA 90 8 (1993) 3665-3669
117. MacDonald A., McLean M., MacAulay L., and Shaw A.M. Effects of propranolol and l-NAME on beta-adrenoceptor-mediated relaxation in rat carotid artery. J Auton Pharmacol 19 3 (1999) 145-149
118. Malina A.N., Laivuori H.M., Agatisa P.K., Collura L.A., Crombleholme W.R., Sims C.J., et al. The Trp64Arg polymorphism of the beta3-adrenergic receptor is not increased in women with preeclampsia. Am J Obstet Gynecol 190 3 (2004) 779-783
119. Mallem M.Y., Gogny M., Gautier F., Bucas V., and Desfontis J.C. Evaluation of beta3-adrenoceptor-mediated relaxation in intact and endotoxin-treated equine digital veins. Am J Vet Res 64 6 (2003) 708-714
120. Mallem M.Y., Toumaniantz G., Serpillon S., Gautier F., Gogny M., Desfontis J.C., et al. Impairment of the low-affinity state beta1-adrenoceptor-induced relaxation in spontaneously hypertensive rats. Br J Pharmacol 143 5 (2004) 599-605
121. Manara L., Badone D., Baroni M., Boccardi G., Cecchi R., Croci T., et al. Functional identification of rat atypical beta-adrenoceptors by the first beta 3-selective antagonists, aryloxypropanolaminotetralins. Br J Pharmacol 117 3 (1996) 435-442
122. Manraj M., Francke S., Hebe A., Ramjuttun U.S., and Froguel P. Genetic and environmental nature of the insulin resistance syndrome in Indo-Mauritian subjects with premature coronary heart disease: contribution of beta3-adrenoreceptor gene polymorphism and beta blockers on triglyceride and HDL concentrations. Diabetologia 44 1 (2001) 115-122
123. Masuo K., Katsuya T., Fu Y., Rakugi H., Ogihara T., and Tuck M.L. Beta2- and beta3-adrenergic receptor polymorphisms are related to the onset of weight gain and blood pressure elevation over 5 years. Circulation 111 25 (2005) 3429-3434
124. Matsushita M., Horinouchi T., Tanaka Y., Tsuru H., and Koike K. Characterization of beta3-adrenoceptor-mediated relaxation in rat abdominal aorta smooth muscle. Eur J Pharmacol 482 1-3 (2003) 235-244
125. Matter C.M., Mandinov L., Kaufmann P.A., Vassalli G., Jiang Z., and Hess O.M. Effect of NO donors on LV diastolic function in patients with severe pressure-overload hypertrophy. Circulation 99 18 (1999) 2396-2401
126. Melis M.G., Secchi G., Brizzi P., Severino C., Maioli M., and Tonolo G. The Trp64Arg beta3-adrenergic receptor amino acid variant confers increased sensitivity to the pressor effects of noradrenaline in Sardinian subjects. Clin Sci (Lond) 103 4 (2002) 397-402
127. 2+ current is regulated by cyclic GMP-dependent protein kinase in mammalian cardiac myocytes. Proc Natl Acad Sci USA 88 4 (1991) 1197-1201
128. Mery P.F., Pavoine C., Belhassen L., Pecker F., and Fischmeister R. Nitric oxide regulates cardiac Ca2+ current. Involvement of cGMP-inhibited and cGMP-stimulated phosphodiesterases through guanylyl cyclase activation. J Biol Chem 268 35 (1993) 26286-26295
129. Michel M.C., Brodde O.E., and Insel P.A. Peripheral adrenergic receptors in hypertension. Hypertension 16 2 (1990) 107-120
130. Milano C.A., Allen L.F., Rockman H.A., Dolber P.C., McMinn T.R., Chien K.R., et al. Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. Science 264 5158 (1994) 582-586
131. Mitchell B.D., Blangero J., Comuzzie A.G., Almasy L.A., Shuldiner A.R., Silver K., et al. A paired sibling analysis of the beta-3 adrenergic receptor and obesity in Mexican Americans. J Clin Invest 101 3 (1998) 584-587
132. Moffett S., Mouillac B., Bonin H., and Bouvier M. Altered phosphorylation and desensitization patterns of a human beta 2-adrenergic receptor lacking the palmitoylated Cys341. EMBO J 12 1 (1993) 349-356
133. Molenaar P., Sarsero D., and Kaumann A.J. Proposal for the interaction of non-conventional partial agonists and catecholamines with the 'putative beta 4-adrenoceptor' in mammalian heart. Clin Exp Pharmacol Physiol 24 9-10 (1997) 647-656
134. Moniotte S., Vaerman J.L., Kockx M.M., Larrouy D., Langin D., Noirhomme P., et al. Real-time RT-PCR for the detection of beta-adrenoceptor messenger RNAs in small human endomyocardial biopsies. J Mol Cell Cardiol 33 12 (2001) 2121-2133
135. Moniotte S., and Balligand J.L. Potential use of beta(3)-adrenoceptor antagonists in heart failure therapy. Cardiovasc Drug Rev 20 1 (2002) 19-26
136. Morimoto A., Hasegawa H., Cheng H.J., Little W.C., and Cheng C.P. Endogenous beta3-adrenoreceptor activation contributes to left ventricular and cardiomyocyte dysfunction in heart failure. Am J Physiol Heart Circ Physiol 286 6 (2004) H2425-H2433
137. Morrison A.C., Brancati F.L., Folsom A.R., Smith L., and Boerwinkle E. Beta3-adrenergic receptor Trp64Arg polymorphism does not predict incident CHD or carotid intima-media thickness in a community-based sample of whites: the ARIC study. Atherosclerosis Risk in Communities. Hum Genet 105 4 (1999) 314-319
138. Nodari S., Metra M., and Dei C.L. Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. Eur J Heart Fail 5 5 (2003) 621-627
139. O'Donnell S.R., and Wanstall J.C. Responses to the beta 2-selective agonist procaterol of vascular and atrial preparations with different functional beta-adrenoceptor populations. Br J Pharmacol 84 1 (1985) 227-235
140. Oizumi T., Daimon M., Saitoh T., Kameda W., Yamaguchi H., Ohnuma H., et al. Genotype Arg/Arg, but not Trp/Arg, of the Trp64Arg polymorphism of the beta(3)-adrenergic receptor is associated with type 2 diabetes and obesity in a large Japanese sample. Diabetes Care 24 9 (2001) 1579-1583
141. O'Shea J.G. Age-related macular degeneration: a leading cause of blindness. Med J Aust 165 10 (1996) 561-564
142. Oriowo M.A. Atypical beta-adrenoceptors in the rat isolated common carotid artery. Br J Pharmacol 113 3 (1994) 699-702
143. Oriowo M.A. Different atypical beta-adrenoceptors mediate isoprenaline-induced relaxation in vascular and non-vascular smooth muscles. Life Sci 56 15 (1995) L269-L275
144. Osswald W., and Guimaraes S. Adrenergic mechanisms in blood vessels: morphological and pharmacological aspects. Rev Physiol Biochem Pharmacol 96 (1983) 53-122
145. Pamies-Andreu E., Garcia-Lozano R., Palmero-Palmero C., Garcia-Morillo S., Alonso-ARcas A., Stiefel P., et al. Genetic variation in the beta-3-adrenergic receptor in essential hypertension. Life Sci 67 4 (2000) 391-397
146. Pavoine C., and Defer N. The cardiac beta2-adrenergic signalling a new role for the cPLA2. Cell Signal 17 2 (2005) 141-152
147. Pavoine C., Behforouz N., Gauthier C., Le Gouvello S., Roudot-Thoraval F., Martin C.R., et al. Beta2-adrenergic signaling in human heart: shift from the cyclic AMP to the arachidonic acid pathway. Mol Pharmacol 64 5 (2003) 1117-1125
148. Pavoine C., Magne S., Sauvadet A., and Pecker F. Evidence for a beta2-adrenergic/arachidonic acid pathway in ventricular cardiomyocytes. Regulation by the beta1-adrenergic/cAMP pathway. J Biol Chem 274 2 (1999) 628-637
149. Pietri-Rouxel F., and Strosberg A.D. Pharmacological characteristics and species-related variations of beta 3-adrenergic receptors. Fundam Clin Pharmacol 9 3 (1995) 211-218
150. Popp B.D., Hutchinson D.S., Evans B.A., and Summers R.J. Stereoselectivity for interactions of agonists and antagonists at mouse, rat and human beta3-adrenoceptors. Eur J Pharmacol 484 2-3 (2004) 323-331
151. Porto P.I., Garcia S.I., Dieuzeide G., Gonzalez C., Landa M.S., and Pirola C.J. Clinical features of the metabolic syndrome in adolescents: minor role of the Trp64Arg beta3-adrenergic receptor gene variant. Pediatr Res 55 5 (2004) 836-841
152. Pott C., Brixius K., Bundkirchen A., Bolck B., Bloch W., Steinritz D., et al. The preferential beta3-adrenoceptor agonist BRL 37344 increases force via beta1/beta2-adrenoceptors and induces endothelial nitric oxide synthase via beta3-adrenoceptors in human atrial myocardium. Br J Pharmacol 138 3 (2003) 521-529
153. Pourageaud F., Leblais V., Bellance N., Marthan R., and Muller B. Role of beta(2)-adrenoceptors (ss-AR), but not ss(1)-, beta(3)-AR and endothelial nitric oxide, in beta-AR-mediated relaxation of rat intrapulmonary artery. Naunyn Schmiedeberg's Arch Pharmacol 372 1 (2005) 14-23
154. Priest R.M., Hucks D., and Ward J.P. Noradrenaline, beta-adrenoceptor mediated vasorelaxation and nitric oxide in large and small pulmonary arteries of the rat. Br J Pharmacol 122 7 (1997) 1375-1384
155. Pulkkinen A., Kareinen A., Saarinen L., Heikkinen S., Lehto S., and Laakso M. The codon 64 polymorphism of the beta3-adrenergic receptor gene is not associated with coronary heart disease or insulin resistance in nondiabetic subjects and non-insulin-dependent diabetic patients. Metabolism 48 7 (1999) 853-856
156. Rautureau Y., Toumaniantz G., Serpillon S., Jourdon P., Trochu J.N., and Gauthier C. Beta 3-adrenoceptor in rat aorta: molecular and biochemical characterization and signalling pathway. Br J Pharmacol 137 2 (2002) 153-161
157. Ringel J., Kreutz R., Distler A., and Sharma A.M. The Trp64Arg polymorphism of the beta3-adrenergic receptor gene is associated with hypertension in men with type 2 diabetes mellitus. Am J Hypertens 13 9 (2000) 1027-1031
158. Riordan J.R., Rommens J.M., Kerem B., Alon N., Rozmahel R., Grzelczak Z., et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245 4922 (1989) 1066-1073
159. Rohrer D.K., Chruscinski A., Schauble E.H., Bernstein D., and Kobilka B.K. Cardiovascular and metabolic alterations in mice lacking both beta1- and beta2-adrenergic receptors. J Biol Chem 274 24 (1999) 16701-16708
160. Rouget C., Breuiller-Fouche M., Mercier F.J., Leroy M.J., Loustalot C., Naline E., et al. The human near-term myometrial beta 3-adrenoceptor but not the beta 2-adrenoceptor is resistant to desensitisation after sustained agonist stimulation. Br J Pharmacol 141 5 (2004) 831-841
161. Rouget C., Barthez O., Goirand F., Leroy M.J., Breuiller-Fouche M., Rakotoniaina Z., et al. Stimulation of the ADRB3 adrenergic receptor induces relaxation of human placental arteries: influence of pre-eclampsia. Biol Reprod (2005)
162. Rozec B., Serpillon S., Toumaniantz G., Seze C., Rautureau Y., and Baron O. Characterization of beta3-adrenoceptors in human internal mammary artery and putative involvement in coronary artery bypass management. J Am Coll Cardiol 46 2 (2005) 351-359
163. Rozec, B., Tran Quang, T., Noireaud, J., & Gauthier, C. (in press). Mixed beta 3-adrenoceptor agonist and alpha 1-adrenoceptor antagonist properties of nebivolol in rat thoracic aorta. Br J Pharmacol.
164. Sakane N., Yoshida T., Yoshioka K., Nakamura Y., Umekawa T., Kogure A., et al. Beta 3-adrenoreceptor gene polymorphism: a newly identified risk factor for proliferative retinopathy in NIDDM patients. Diabetes 46 10 (1997) 1633-1636
165. Sakane N., Yoshida T., Yoshioka K., Nakamura Y., Umekawa T., Kogure A., et al. Trp64Arg mutation of beta3-adrenoceptor gene is associated with diabetic nephropathy in Type II diabetes mellitus. Diabetologia 41 12 (1998) 1533-1534
166. Sarsero D., Russell F.D., Lynham J.A., Rabnott G., Yang I., Fong K.M., et al. (-)-CGP 12177 increases contractile force and hastens relaxation of human myocardial preparations through a propranolol-resistant state of the beta 1-adrenoceptor. Naunyn Schmiedeberg's Arch Pharmacol 367 1 (2003) 10-21
167. Schranz D., Droege A., Broede A., Brodermann G., Schafer E., Oelert H., et al. Uncoupling of human cardiac beta-adrenoceptors during cardiopulmonary bypass with cardioplegic cardiac arrest. Circulation 87 2 (1993) 422-426
168. Schulz R., Rassaf T., Massion P.B., Kelm M., and Balligand J.L. Recent advances in the understanding of the role of nitric oxide in cardiovascular homeostasis. Pharmacol Ther 108 3 (2006) 225-256
169. Sellke F.W., Tofukuji M., Stamler A., Li J., and Wang S.Y. Beta-adrenergic regulation of the cerebral microcirculation after hypothermic cardiopulmonary bypass. Circulation 96 9 Suppl (1997) II-10
170. Sennitt M.V., Kaumann A.J., Molenaar P., Beeley L.J., Young P.W., Kelly J., et al. The contribution of classical (beta1/2-) and atypical beta-adrenoceptors to the stimulation of human white adipocyte lipolysis and right atrial appendage contraction by novel beta3-adrenoceptor agonists of differing selectivities. J Pharmacol Exp Ther 285 3 (1998) 1084-1095
171. Shafiei M., Omrani G., and Mahmoudian M. Coexistence of at least three distinct beta-adrenoceptors in human internal mammary artery. Acta Physiol Hung 87 3 (2000) 275-286
172. 2+ in intact cardiac myocytes. Circ Res 74 5 (1994) 970-978
173. Shen Y.T., Cervoni P., Claus T., and Vatner S.F. Differences in beta 3-adrenergic receptor cardiovascular regulation in conscious primates, rats and dogs. J Pharmacol Exp Ther 278 3 (1996) 1435-1443
174. Shen Y.T., Zhang H., and Vatner S.F. Peripheral vascular effects of beta-3 adrenergic receptor stimulation in conscious dogs. J Pharmacol Exp Ther 268 1 (1994) 466-473
175. Sheu W.H., Lee W.J., Yao Y.E., Jeng C.Y., Young M.M., and Chen Y.T. Lack of association between genetic variation in the beta3-adrenergic receptor gene and insulin resistance in patients with coronary heart disease. Metabolism 48 5 (1999) 651-654
176. Stangl K., Cascorbi I., Laule M., Stangl V., Meisel C., and Wernecke K.D. The beta3-adrenergic receptor Trp64Arg mutation is not associated with coronary artery disease. Metabolism 50 2 (2001) 184-188
177. Steinle J.J., Booz G.W., Meininger C.J., Day J.N., and Granger H.J. Beta 3-adrenergic receptors regulate retinal endothelial cell migration and proliferation. J Biol Chem 278 23 (2003) 20681-20686
178. Steinle J.J., Zamora D.O., Rosenbaum J.T., and Granger H.J. Beta 3-adrenergic receptors mediate choroidal endothelial cell invasion, proliferation, and cell elongation. Exp Eye Res 80 1 (2005) 83-91
179. Strazzullo P., Iacone R., Siani A., Cappuccio F.P., Russo O., Barba G., et al. Relationship of the Trp64Arg polymorphism of the beta3-adrenoceptor gene to central adiposity and high blood pressure: interaction with age. Cross-sectional and longitudinal findings of the Olivetti Prospective Heart Study. J Hypertens 19 3 (2001) 399-406
180. Strosberg A.D. Structure and function of the beta 3-adrenergic receptor. Annu Rev Pharmacol Toxicol 37 (1997) 421-450
181. Strosberg A.D., and Pietri-Rouxel F. Function and regulation of the beta 3-adrenoceptor. Trends Pharmacol Sci 17 10 (1996) 373-381
182. Summers R.J., Kompa A., and Roberts S.J. Beta-adrenoceptor subtypes and their desensitization mechanisms. J Auton Pharmacol 17 6 (1997) 331-343
183. Susulic V.S., Frederich R.C., Lawitts J., Tozzo E., Kahn B.B., Harper M.E., et al. Targeted disruption of the beta 3-adrenergic receptor gene. J Biol Chem 270 49 (1995) 29483-29492
184. Tagaya E., Tamaoki J., Takemura H., Isono K., and Nagai A. Atypical adrenoceptor-mediated relaxation of canine pulmonary artery through a cyclic adenosine monophosphate-dependent pathway. Lung 177 5 (1999) 321-332
185. Takahashi H., Yoshida T., Nishimura M., Nakanishi T., Kondo M., and Yoshimura M. Beta-3 adrenergic agonist, BRL-26830A, and alpha/beta blocker, arotinolol, markedly increase regional blood flow in the brown adipose tissue in anesthetized rats. Jpn Circ J 56 9 (1992) 936-942
186. Takayama S., Furukawa Y., Ren L.M., Inoue Y., Sawaki S., and Chiba S. Positive chronotropic and inotropic responses to BRL 37344, a beta 3-adrenoceptor agonist in isolated, blood-perfused dog atria. Eur J Pharmacol 231 3 (1993) 315-321
187. Tamaki S., Iwai N., Tsujita Y., Nakamura Y., Ohmichi N., and Kinoshita M. Variant of the beta3-adrenergic receptor gene and coronary atherosclerosis in Japanese subjects. Int J Cardiol 69 3 (1999) 309-311
188. Tamaoki J., Tagaya E., Isono K., and Nagai A. Atypical adrenoceptor-mediated relaxation of canine pulmonary artery through a cAMP-dependent pathway. Biochem Biophys Res Commun 248 3 (1998) 722-727
189. Tavernier G., Galitzky J., Bousquet-Melou A., Montastruc J.L., and Berlan M. The positive chronotropic effect induced by BRL 37344 and CGP 12177, two beta-3 adrenergic agonists, does not involve cardiac beta adrenoceptors but baroreflex mechanisms. J Pharmacol Exp Ther 263 3 (1992) 1083-1090
190. Tavernier G., Toumaniantz G., Erfanian M., Heymann M.F., Laurent K., Langin D., et al. Beta3-adrenergic stimulation produces a decrease of cardiac contractility ex vivo in mice overexpressing the human beta3-adrenergic receptor. Cardiovasc Res 59 2 (2003) 288-296
191. Thomas G.N., Tomlinson B., Chan J.C., Young R.P., and Critchley J.A. The Trp64Arg polymorphism of the beta3-adrenergic receptor gene and obesity in Chinese subjects with components of the metabolic syndrome. Int J Obes Relat Metab Disord 24 5 (2000) 545-551
192. Thuillez C., and Richard V. Targeting endothelial dysfunction in hypertensive subjects. J Hum Hypertens 19 Suppl 1 (2005) S21-S25
193. Toda N. Vasodilating beta-adrenoceptor blockers as cardiovascular therapeutics. Pharmacol Ther 100 3 (2003) 215-234
194. Tonolo G., Melis M.G., Secchi G., Atzeni M.M., Angius M.F., Carboni A., et al. Association of Trp64Arg beta 3-adrenergic-receptor gene polymorphism with essential hypertension in the Sardinian population. J Hypertens 17 1 (1999) 33-38
195. Torres J., Darley-Usmar V., and Wilson M.T. Inhibition of cytochrome c oxidase in turnover by nitric oxide: mechanism and implications for control of respiration. Biochem J 312 Pt 1 (1995) 169-173
196. Trochu J.N., Leblais V., Rautureau Y., Beverelli F., Le Marec H., Berdeaux A., et al. Beta 3-adrenoceptor stimulation induces vasorelaxation mediated essentially by endothelium-derived nitric oxide in rat thoracic aorta. Br J Pharmacol 128 1 (1999) 69-76
197. Turner N.C., and White P. Effects of streptozotocin-induced diabetes on vascular reactivity in genetically hyperinsulinaemic obese Zucker rats. J Cardiovasc Pharmacol 27 6 (1996) 884-890
198. Uydes-Dogan B.S., Nebigil M., Aslamaci S., Onuk E., Kanzik I., and Akar F. The comparison of vascular reactivities of arterial and venous grafts to vasodilators: management of graft spasm. Int J Cardiol 53 2 (1996) 137-145
199. van Spronsen A., Nahmias C., Krief S., Briend-Sutren M.M., Strosberg A.D., and Emorine L.J. The promoter and intron/exon structure of the human and mouse beta 3-adrenergic-receptor genes. Eur J Biochem 213 3 (1993) 1117-1124
200. Varghese P., Harrison R.W., Lofthouse R.A., Georgakopoulos D., Berkowitz D.E., and Hare J.M. Beta(3)-adrenoceptor deficiency blocks nitric oxide-dependent inhibition of myocardial contractility. J Clin Invest 106 5 (2000) 697-703
201. Viard P., Macrez N., Coussin F., Morel J.L., and Mironneau J. Beta-3 adrenergic stimulation of L-type Ca(2+) channels in rat portal vein myocytes. Br J Pharmacol 129 7 (2000) 1497-1505
202. Wahler G.M., and Dollinger S.J. Nitric oxide donor SIN-1 inhibits mammalian cardiac calcium current through cGMP-dependent protein kinase. Am J Physiol 268 1 Pt 1 (1995) C45-C54
203. Walston J., Silver K., Bogardus C., Knowler W.C., Celi F.S., Austin S., et al. Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the beta 3-adrenergic-receptor gene. N Engl J Med 333 6 (1995) 343-347
204. Walston J., Lowe A., Silver K., Yang Y., Bodkin N.L., Hansen B.C., et al. The beta3-adrenergic receptor in the obesity and diabetes prone rhesus monkey is very similar to human and contains arginine at codon 64. Gene 188 2 (1997) 207-213
205. Wang Q., Curran M.E., Splawski I., Burn T.C., Millholland J.M., VanRaay T.J., et al. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet 12 1 (1996) 17-23
206. Warth J.D., Collier M.L., Hart P., Geary Y., Gelband C.H., Chapman T., et al. CFTR chloride channels in human and simian heart. Cardiovasc Res 31 4 (1996) 615-624
207. Werstiuk E.S., and Lee R.M. Vascular beta-adrenoceptor function in hypertension and in ageing. Can J Physiol Pharmacol 78 6 (2000) 433-452
208. Wheeldon N.M., McDevitt D.G., and Lipworth B.J. Investigation of putative cardiac beta 3-adrenoceptors in man. Q J Med 86 4 (1993) 255-261
209. Wheeldon N.M., McDevitt D.G., and Lipworth B.J. Cardiac effects of the beta 3-adrenoceptor agonist BRL35135 in man. Br J Clin Pharmacol 37 4 (1994) 363-369
210. Widen E., Lehto M., Kanninen T., Walston J., Shuldiner A.R., and Groop L.C. Association of a polymorphism in the beta 3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns. N Engl J Med 333 6 (1995) 348-351
211. Wilson S., Chambers J.K., Park J.E., Ladurner A., Cronk D.W., Chapman C.G., et al. Agonist potency at the cloned human beta-3 adrenoceptor depends on receptor expression level and nature of assay. J Pharmacol Exp Ther 279 1 (1996) 214-221
212. Xiang K., Jia W., Lu H., Zheng T., Lu J., and Tang J. Effects of Trp64Arg mutation in the beta 3-adrenergic receptor gene on body fat, plasma glucose level, lipid profile, insulin secretion and action in Chinese. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 15 6 (1998) 337-340
213. Xiao R.P., Cheng H., Zhou Y.Y., Kuschel M., and Lakatta E.G. Recent advances in cardiac beta(2)-adrenergic signal transduction. Circ Res 85 11 (1999) 1092-1100
214. Xiu L.L., Weng J.P., Sui Y., Wang J., Yan J.H., and Huang Z.M. Common variants in beta 3-adrenergic-receptor and uncoupling protein-2 genes are associated with type 2 diabetes and obesity. Zhonghua Yi Xue Za Zhi 84 5 (2004) 375-379
215. Yasuda S., and Lew W.Y. Lipopolysaccharide depresses cardiac contractility and beta-adrenergic contractile response by decreasing myofilament response to Ca2+ in cardiac myocytes. Circ Res 81 6 (1997) 1011-1020
216. Yousif M.H., and Oriowo M.A. BRL 37344 inhibited adrenergic transmission in the rat portal vein via atypical beta-adrenoceptors. Pharmacol Res 45 4 (2002) 313-317
217. Zhang C., Williams M.A., Edwards K.L., and Austin M.A. Trp64Arg polymorphism of the beta3-adrenergic receptor gene, pre-pregnancy obesity and risk of pre-eclampsia. J Matern Fetal Neonatal Med 17 1 (2005) 19-28
218. 2+ current by {beta}3-adrenergic stimulation in failing rat heart. J Pharmacol Exp Ther. 315 3 (2005) 1203-1211